Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack
Status:
Recruiting
Trial end date:
2023-09-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in
addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI),
for the prevention of hospitalisation for heart failure (HHF) or cardiovascular (CV) death.